Merrill puts Adolor at buy

Merrill Lynch analyst David Munno rated Adolor Corp. at buy on possible overreaction to the Food and Drug Administration's approvable letter for Entereg in post-operative ileus. The FDA did not request any new efficacy data, suggesting that the data from study 314 demonstrated sufficient improvement in GI recovery. For long-term investors, Munno believes the stock is more than pricing and would buy on weakness. Shares of the Exton, Pa.-based biopharmaceutical company were down $6.25, or 44.84%, at $7.69. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.